[HTML][HTML] The role of a single angiogenesis inhibitor in the treatment of recurrent glioblastoma multiforme: a meta-analysis and systematic review
Y Wang, D Xing, M Zhao, J Wang, Y Yang - PLoS One, 2016 - journals.plos.org
Background Currently, the standard treatment for newly diagnosed glioblastoma multiforme
(GBM) is maximal safe surgical resection followed by radiation therapy with concurrent and …
(GBM) is maximal safe surgical resection followed by radiation therapy with concurrent and …
[HTML][HTML] Current development of anti-cancer drug S-1
P Chhetri, A Giri, S Shakya, S Shakya… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
S-1 is a novel oral fluoropyrimidine derivative, widely used for treating gastric, pancreatic,
lung, head, neck and breast carcinomas. It is designed to enhance the clinical utility of an …
lung, head, neck and breast carcinomas. It is designed to enhance the clinical utility of an …
Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell …
T Wang, SF Zhang, MQ Qiu, QL Li - Cancer/radiothérapie, 2016 - Elsevier
Purpose This study evaluated the efficacy and safety of the combination drug tegafur,
gimeracil, and oteracil potassium (S-1) concurrent with 3-dimensional conformal …
gimeracil, and oteracil potassium (S-1) concurrent with 3-dimensional conformal …
[HTML][HTML] Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study
Y Takiguchi, T Seto, Y Ichinose, N Nogami… - Journal of Thoracic …, 2011 - Elsevier
Background: Standard second-line chemotherapies for non-small cell lung cancer (NSCLC)
have been established but have limited clinical relevance. S-1 is a recently developed agent …
have been established but have limited clinical relevance. S-1 is a recently developed agent …
Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer
K Kaira, N Sunaga, N Yanagitani, H Imai, M Utsugi… - Lung Cancer, 2010 - Elsevier
We conducted a phase II study of S-1 and carboplatin combination regimen in the treatment
of patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-naïve …
of patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-naïve …
[HTML][HTML] Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split‑dose administration of cisplatin after complete resection of stage II‑IIIA non‑small cell …
N Funaguchi, H Iihara, D Kaito… - Molecular and …, 2022 - spandidos-publications.com
Although co‑administration of cisplatin (CDDP) and vinorelbine (VNR) has been established
as a standard of care adjuvant chemotherapy for non‑small cell lung cancer (NSCLC), there …
as a standard of care adjuvant chemotherapy for non‑small cell lung cancer (NSCLC), there …
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial …
K Akie, S Oizumi, S Ogura, N Shinagawa, E Kikuchi… - Oncology, 2011 - karger.com
Objective: Platinum-free regimens can represent an alternative for advanced non-small cell
lung cancer (NSCLC) if similar efficacy is provided with better tolerability. This study …
lung cancer (NSCLC) if similar efficacy is provided with better tolerability. This study …
[PDF][PDF] 替吉奥联合伽马刀治疗食管癌腹膜后淋巴结转移的临床观察
葛摇宁， 詹必红， 常摇娜， 臧春宝 - 蚌埠医学院学报, 2015 - xuebao.bbmc.edu.cn
替吉奥联合伽马刀治疗食管癌腹膜后淋巴结转移的临床观察 Page 1 [收稿日期] 2015鄄06鄄01 [作者
单位] 安徽省肿瘤医院放疗科,安徽合肥230031 [作者简介] 葛摇宁(1981 - ),男,硕士,住院医师. [文章 …
单位] 安徽省肿瘤医院放疗科,安徽合肥230031 [作者简介] 葛摇宁(1981 - ),男,硕士,住院医师. [文章 …